Literature DB >> 8221621

The role of reduced growth rate in the development of drug resistance of HOB1 lymphoma cells to vincristine.

W P Lee1.   

Abstract

An MDR cell line resistant to 1.0 microM vincristine (designated HOB1/VCR1.0) was established. The growth rate of HOB1/VCR1.0 cells was slow. The cells did not go into active proliferation although the drug treatment was released for two months (revertant cells). The HOB1/VCR1.0 cell line and its revertant were resistant to a high dose of vincristine (up to 20 microM). These two cell lines showed a decrease in expression of the hyperphosphorylated form of the retinoblastoma protein, of which the hypophosphorylated form has been considered to be a tumor suppressor. Similar phenomena were observed in the parental cells surviving brief treatment with a lethal dose of vincristine (0.05 microM). The current study gives the impression that self-inhibited growth rate may participate in the initial drug resistance before the expression of P-glycoprotein when tumor cells are suddenly exposed to chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221621     DOI: 10.1016/0304-3835(93)90251-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival.

Authors:  Praful R Nair; Cory Alvey; Xiaoling Jin; Jerome Irianto; Irena Ivanovska; Dennis E Discher
Journal:  Bioconjug Chem       Date:  2018-03-01       Impact factor: 4.774

2.  Phenotypic and transcriptional profiling in Entamoeba histolytica reveal costs to fitness and adaptive responses associated with metronidazole resistance.

Authors:  Gil M Penuliar; Kumiko Nakada-Tsukui; Tomoyoshi Nozaki
Journal:  Front Microbiol       Date:  2015-05-05       Impact factor: 5.640

3.  Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment.

Authors:  James M Greene; Jana L Gevertz; Eduardo D Sontag
Journal:  JCO Clin Cancer Inform       Date:  2019-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.